Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Apr 26, 2022; 10(12): 3677-3685
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3677
Table 1 Clinical characteristics of study population

n
Overall
mRS 0–3 (n = 33)
mRS 4–6 (n = 66)
P value
Age (yr)9967 (60.2, 76)65.8 (60.4, 74)67.9 (59.5, 76.3)0.689
Women, n (%)9932 (32.3)9 (27.3)23 (34.6)0.447
Initial NIHSS (IQR)9925 (14, 30)11 (7, 25)29 (23, 33)< 0.001
Risk factors, n (%)
Hypertension9981 (81.8)28 (84.9)53 (80.3)0.580
Diabetes mellitus9943 (43.4)15 (45.5)28 (42.4)0.774
Atrial fibrillation9935 (35.3)10 (30.3)25 (37.9)0.457
Hyperlipidemia9937 (37.4)16 (48.5)21 (31.8)0.106
CAD9915 (15.1)8 (24.2)7 (10.6)0.074
Previous stroke9923 (23.2)6 (18.2)17 (25.8)0.400
Smoking 9946 (46.5)17 (51.5)29 (43.9)0.476
Etiology, n (%)981
Large-artery artherosclerosis66 (67.3)22 (66.7)44 (67.7)
Cardioembolism 5 (5.1)2 (6.1)3 (4.6)
Stroke of undetermined etiology 27 (27.6)9 (27.3)18 (27.7)
Prodromal symptoms, n (%)
Vertigo or dizziness9927 (27.3)12 (36.4)15 (22.7)0.151
Confusion 9910 (10.1)3 (9.1)7 (10.6)1
Unsteady gait9914 (14.1)6 (18.2)8 (12.1)0.542
BAO symptoms, n (%)
Duration hours, median (IQR)984 (2, 10)3.5 (2, 10)4 (3, 10)0.552
Impaired consciousness, n (%)9976 (76.8)19 (57.6)57 (86.4)0.001
Tetraparesis, n (%)9957 (57.6)9 (27.3)48 (72.7)< 0.001
Bulbar symptoms9975 (75.6)26 (78.8)49 (74.2)0.619
Cerebellar symptoms, n (%) 9921 (21.2)12 (36.4)9 (13.6)0.009
Vertigo or dizziness9932 (32.3)13 (39.4)19 (28.8)0.288
Nausea 9917 (17.2)8 (24.2)9 (13.6)0.187
Oculomotor abnormalities 9968 (68.7)19 (57.6)49 (74.2)0.092
Pupillary abnormalities, n (%)9942 (42.4)9 (27.3)33 (50)0.031
IAT9972 (72.7)21 (63.6)51 (77.3)0.151
IV tPA9913 (13.1)4 (12.1)9 (13.6)1
SICH995 (5)1 (3)4 (6)